Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Recurrent Non-small Cell Lung Cancer
and you are
between 18 and 75
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

Provided treatments

  • Drug: Cisplatin
  • Drug: Carboplatin
  • Drug: Docetaxel
  • Drug: Gemcitabine/Carboplatin
  • Drug: Gemcitabine/Cisplatin
  • Drug: Docetaxel/Oxaliplatin
  • Drug: Docetaxel/Carboplatin
  • Drug: Placebo
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02889666. The sponsor of the trial is Shanghai Jiao Tong University School of Medicine and it is looking for 500 volunteers for the current phase.
Official trial title:
A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery as Treatment for Relapsed and Refractory Non-Small Cell Lung Cancer